Step 6: In-Vivo Studies

  1. Radhakrishnan, P., Bryant, V. C., Blowers, E. B., Rajule, R. N., Gautam, N., Anwar, M. M., Mohr, A. M., Grandgenett, P. A., Bunt, S. K., Arnst, J. L., Lele, S. M., Alnouti, Y., Hollingsworth, M. A., Natarajan, A.* “Targeting the NF-κB and mTOR pathways with a quinoxaline urea analog that inhibits IKKβ for pancreas cancer therapy” Clin. Cancer Res. 2013, 19, 2025-2035. PMCID: PMC3630250

  2. Chaturvedi, N. K., Rajule, R. N., Shukla, A., Radhakrishnan, P., Todd, G. L., Natarajan, A., Vose, J. M., Joshi S. S. “Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual targeting approach” Mol. Cancer Ther. 2013, 12, 2006-2017. PMCID: PMC4124828

  3. Rana, S., Blowers, E. B., Tebbe, C., Contreras, J. I., Radhakrishnan, P., Kizhake, S., Zhou, T., Rajule, R. N., Arnst, J. L., Munkarah, A., Rattan, R., Natarajan, A.* “Isatin derived spirocyclic analogs with α-methylene-γ-butyrolactone as anticancer agents: A structure activity relationship study” J. Med. Chem. 2016, 59, 5121-27. PMCID: PMC5273401.

  4. Robb, C. M., Kour, S., Contreras, J. I., Agarwal, E., Carter, B., Rana, S., Sonawane, Y. A., Neilsen, B., Taylor, M. A., Kizhake, S., Thakare, R., Chowdhury, S., Wang, J., Black, J., Hollingsworth, M. A., Brattain, M., Natarajan, A.* “Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy" Oncotarget, 2018, 9, 5216-5232. PMCID: PMC5797045.

  5. Sagar, S., Singh, S., Mallareddy, J. R., Sonawane, Y. A., Napoleon, J. V., Rana, S., Contreras, J. I., Rajesh, C., Ezell, E. L., Kizhake, S., Garrison, J. C., Radhakrishnan, P., Natarajan, A.* “Structure activity relationship (SAR) study identifies a quinoxaline urea analog that modulates IKKβ phosphorylation for pancreatic cancer therapy” Eur. J. Med. Chem. 2021, 222(113579) 1-15. PMCID: PMC8373685.

  6. Napoleon, J. V., Sagar, S., Kubica, S. P., Boghean, L., Kour, S., King, H. M., Sonawane, Y. A., Crawford, A. J., Gautam, N., Kizhake, S., Bialk, P. A., Kmiec, E., Mallareddy, J. R., Patil, P., Rana, S., Singh, S., Prahlad, J., Grandgenett, P.M., Borgstahl, G. E. O., Ghosal, G., Alnouti, Y., Hollingsworth, M.A., Radhakrishnan, P., Natarajan, A.* “Small molecule IKKβ activation modulator (IKAM) targets MAP3K1 and inhibits pancreatic tumor growth” Proc. Natl. Acad. Sci. USA 2022, 119(18):e2115071119 PMCID: PMC9170026.

  7. Umfress, A., Chakraborti, A., Priya, S., Adams, R., Epstein, D., Massicano, A., Sorace, A., Singh, S., Hossian, I., Anrabi, S., Crossman, D., Kumar, N., Mukhtar, S., Simpson, C., Stokes, M., Widerhold, T., Rosen, C., Luo, H., Lu, H., Natarajan, A., Bibb, J. A. “Cdk5 mediates rotational force-induced brain injury” Sci. Rep. 2023, 13(1), 3394 doi.org/10.1038/s41598-023-29322-4 PMCID: PMC9974974.

  8. Eiken, A. P., Smith, A. L., Skupa, S. A., Schmitz, E., Rana, S., Singh, S., Kumar, S., Mallareddy, J. R., de Cubas, A. A., Krishna, A., Kalluchi, A., Rowley, M. J., D’Angelo, C. R., Lunning, M. A., Bociek, R. G., Vose, J. M., Natarajan, A., El-Gamal, D. “Novel spirocyclic dimer, SpiD3, targets chronic lymphocytic leukemia survival pathways with potent preclinical effects” Cancer Res. Commun. 2024, 4(5), 1328-1343. PMCID: PMC11110724.

1. Target Identification To Validation